钙调蛋白突变临床表现:国际钙调蛋白病登记研究
国际钙调蛋白病登记研究(ICalmR)纳入140例CALM阳性患者,中位年龄10.8岁,CALM-LQTS和CALM-CPVT为主要表型,20例有原发性神经系统表现,30%存在心脏结构异常,心律失常事件率高但较2019年队列频率和严重程度降低。
要点
- 钙调蛋白病表型多样,从离子通道病到综合征形式,严重程度从早发致命性心律失常到无症状不等。
- CALM-LQTS和CALM-CPVT为主要表型,30%患者存在心脏结构异常(心肌病或先天性心脏缺陷)。
- 与2019年队列相比,所有心脏事件频率和严重程度降低(61% vs. 85%),猝死减少(9% vs. 27%)。
核心结论
- 钙调蛋白病具有多效性表现,从离子通道病到综合征形式,临床严重程度范围广,较轻和家族性形式比例增加。
研究设计与样本
- 国际协作观察性研究,纳入140例CALM阳性患者(97例先证者,43例家庭成员),中位年龄10.8岁(四分位距5-19)。
主要发现
- CALM-LQTS和CALM-CPVT是主要表型,20例患者出现与缺氧后遗症无关的原发性神经系统表现。
- 30%患者存在心脏结构异常(心肌病或先天性心脏缺陷),主要见于CALM-LQTS,并发生致命性心力衰竭病例。
- 家族性病例和表型显著不同的家族数量增加。
关键数值与推荐
- 心脏结构异常存在于30%患者中,主要见于CALM-LQTS。
- 治疗数据不足以提供确定性推荐。
临床怎么用
- 当前管理包括药物和手术抗肾上腺素能干预,常联用钠通道阻滞剂,并常伴随植入式心律转复除颤器。
- 治疗数据不足以给出确定性推荐。
局限性
- 治疗数据不足以提供确定性推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Calmodulinopathy due to mutations in any of the three CALM genes (CALM1-3) causes life-threatening arrhythmia syndromes, especially in young individuals. The International Calmodulinopathy Registry (ICalmR) aims to define and link the increasing complexity of the clinical presentation to the underlying molecular mechanisms. METHODS AND RESULTS: The ICalmR is an international, collaborative, observational study, assembling and analysing clinical and genetic data on CALM-positive patients. The ICalmR has enrolled 140 subjects (median age 10.8 years [interquartile range 5-19]), 97 index cases and 43 family members. CALM-LQTS and CALM-CPVT are the prevalent phenotypes. Primary neurological manifestations, unrelated to post-anoxic sequelae, manifested in 20 patients. Calmodulinopathy remains associated with a high arrhythmic event rate (symptomatic patients, n = 103, 74%). However, compared with the original 2019 cohort, there was a reduced frequency and severity of all cardiac events (61% vs. 85%; P = .001) and sudden death (9% vs. 27%; P = .008). Data on therapy do not allow definitive recommendations. Cardiac structural abnormalities, either cardiomyopathy or congenital heart defects, are present in 30% of patients, mainly CALM-LQTS, and lethal cases of heart failure have occurred. The number of familial cases and of families with strikingly different phenotypes is increasing. CONCLUSION: Calmodulinopathy has pleiotropic presentations, from channelopathy to syndromic forms. Clinical severity ranges from the early onset of life-threatening arrhythmias to the absence of symptoms, and the percentage of milder and familial forms is increasing. There are no hard data to guide therapy, and current management includes pharmacological and surgical antiadrenergic interventions with sodium channel blockers often accompanied by an implantable cardioverter-defibrillator.
引用
- Crotti L, Spazzolini C, Nyegaard M, et al. Clinical presentation of calmodulin mutations: the International Calmodulinopathy Registry. Eur Heart J. 2023. PMID: 37528649. doi:10.1093/eurheartj/ehad418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。